Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rybrevant
Pharma
J&J combo survival win signals new era in EGFR lung cancer
The J&J combo of Rybrevant and Lazcluze is expected to offer at least an extra year of life versus Tagrisso in first-line EGFR lung cancer.
Angus Liu
Mar 26, 2025 11:45am
J&J's Rybrevant-Lazcluze tops AZ's Tagrisso on overall survival
Jan 7, 2025 8:00am
J&J, AZ approval filings rejected by FDA
Dec 17, 2024 10:02am
EU regulators endorse meds from BMS, J&J, Eisai and more
Nov 15, 2024 10:05am
FDA expands label for AZ's Tagrisso in NSCLC indication
Sep 26, 2024 10:52am
J&J earns 3rd NSCLC nod in 7 months for surging Rybrevant
Sep 20, 2024 11:00am
